全文获取类型
收费全文 | 3250篇 |
免费 | 337篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 101篇 |
妇产科学 | 64篇 |
基础医学 | 310篇 |
口腔科学 | 157篇 |
临床医学 | 401篇 |
内科学 | 749篇 |
皮肤病学 | 164篇 |
神经病学 | 154篇 |
特种医学 | 177篇 |
外科学 | 509篇 |
综合类 | 105篇 |
现状与发展 | 30篇 |
预防医学 | 262篇 |
眼科学 | 34篇 |
药学 | 180篇 |
中国医学 | 14篇 |
肿瘤学 | 167篇 |
出版年
2024年 | 19篇 |
2023年 | 190篇 |
2022年 | 31篇 |
2021年 | 64篇 |
2020年 | 81篇 |
2019年 | 81篇 |
2018年 | 113篇 |
2017年 | 95篇 |
2016年 | 82篇 |
2015年 | 114篇 |
2014年 | 158篇 |
2013年 | 149篇 |
2012年 | 142篇 |
2011年 | 143篇 |
2010年 | 153篇 |
2009年 | 142篇 |
2008年 | 106篇 |
2007年 | 145篇 |
2006年 | 130篇 |
2005年 | 114篇 |
2004年 | 80篇 |
2003年 | 104篇 |
2002年 | 73篇 |
2001年 | 63篇 |
2000年 | 76篇 |
1999年 | 84篇 |
1998年 | 55篇 |
1997年 | 71篇 |
1996年 | 63篇 |
1995年 | 49篇 |
1994年 | 46篇 |
1993年 | 47篇 |
1992年 | 41篇 |
1991年 | 39篇 |
1990年 | 55篇 |
1989年 | 53篇 |
1988年 | 38篇 |
1987年 | 39篇 |
1986年 | 22篇 |
1985年 | 21篇 |
1984年 | 28篇 |
1983年 | 20篇 |
1982年 | 17篇 |
1981年 | 21篇 |
1980年 | 15篇 |
1979年 | 17篇 |
1978年 | 16篇 |
1976年 | 16篇 |
1975年 | 18篇 |
1974年 | 11篇 |
排序方式: 共有3614条查询结果,搜索用时 15 毫秒
41.
Zhang JD Cao YB Xu Z Sun HH An MM Yan L Chen HS Gao PH Wang Y Jia XM Jiang YY 《第二军医大学学报》2006,27(6):664-664
Antifungal activity of natural products is being studied widely. Saponins are known to be antifungal and antibacterial. We have isolated eight steroid saponins from Tribulus terrestris L. , namely TTS-8, TTS-9, TTS-10, TTS-11, TTS-12, TTS-13, TTS-14 and TTS-15. TTS-12 and TTS-15 were identified as tigogenin-3-O-β-D-xylopyranosyl(1→ 2)-[-β-D-xylopyranosyl( 1 → 3 ) 3-β- D-glucopyranosyl ( 1 → 4 )- 1- α-L-rhamnopyranosyl ( 1 → 2 ) 3-β-D-galactopyranoside and tigogenin-3-O-β-D-glucopyranpyranosyl(1→2)-[-β-D-xylopyranosyl(1→ 3)3-β-D-glucopyranosyl(1→4)-β-D-galactopyranoside, respectively. The in vitro antifungal activities of the eight saponins against six fluconazole-resistant yeasts, Candida albicans, Candida glabrata, Candida para psilosis , Candida tropicalis , Candida krusei , and Cryptococcus neo f ormans were studied using microbroth dilution assay. The results showed that TTS-12 and TTS-15 were very effective against several pathogenic candidal species and C. neoformans in vitro. It is noteworthy that TTS-12 and TTS-15 were very active against fluconazole-resistant C. albicans (MIC80 = 4.4, 9.4 mg/ml), C. neoformans (MIC80 =10.7, 18.7 mg/ml) and inherently resistant C. krusei (MIC80 =8.8, 18.4 mg/ml). So in vivo activity of TTS-12 in a vaginal infection model with fluconazole-resistant C. albicans was studied in particular. Our studies revealed TTS-12 also showed in vivo activities against fluconazole-resistant yeasts. In conclusion, steroid saponins TTS-12 and TTS-15 from Tribulus terrestris L. have significant in vitro antifungal activity against fluconazole-resistant fungi, especially TTS-12 also showed in vivo activity against fluconazole-resistant C. albicans. 相似文献
42.
Susana B Bravo María E R García-Rendueles Rafael Seoane Vanesa Dosil José Cameselle-Teijeiro Luis López-Lázaro Juan Zalvide Francisco Barreiro Celia M Pombo Clara V Alvarez 《Clinical cancer research》2005,11(21):7664-7673
Undifferentiated (anaplastic) thyroid carcinoma is a highly aggressive human cancer with very poor prognosis. Although there have been a few studies of candidate treatments, the fact that it is an infrequent tumor makes it very difficult to design clinical trials. A strong association has been observed between undifferentiated thyroid carcinoma and TP53 mutations in numerous molecular genetic and expression studies. Plitidepsin (Aplidin, PharmaMar, Madrid, Spain) is a novel anticancer compound obtained from a sea tunicate. This compound has been reported to induce apoptosis independently of TP53 status. We investigated the actions of plitidepsin in human thyroid cancer cells. In initial experiments using primary cultured cells from a differentiated (papillary) carcinoma, we found that 100 nmol/L plitidepsin induced apoptosis, whereas lower doses were cytostatic. Because our aim was to study the effects of plitidepsin at clinically relevant concentrations, subsequent experiments were done with a dosage regimen reflecting plasma concentrations observed in previously reported clinical trials: 100 nmol/L for 4 hours, followed by 10 nmol/L for 20 hours (4(100)/20(10) plitidepsin). This plitidepsin dosage regimen blocked the proliferation of a primary undifferentiated/anaplastic thyroid carcinoma culture obtained in our laboratory and of a commercial cell line (8305C) obtained from an undifferentiated thyroid carcinoma; however, it did not induce apoptosis. The proportion of cells in the G(1) phase of the cell cycle was greatly increased and the proportion in the S/G(2)-M phases greatly reduced, suggesting that plitidepsin blocks G(1)-to-S transition. Levels of the cyclin D1/cyclin-dependent kinase 4/p21 complex proteins were decreased and, in line with this, the levels of unphosphorylated Rb1 increased. The decrease in cell cycle proteins correlated with hypoacetylation of histone H3. Finally, we did experiments to assess how rapidly tumor cells return to their initial pretreatment proliferative behavior after 4(100)/20(10) plitidepsin treatment. Cells from undifferentiated tumors needed more than 3 days to recover logarithmic growth, and after 7 days, cell number was still significantly lower than in control cultures. 4(100)/20(10) plitidepsin inhibited the growth in soft agar. Together, our data show that plitidepsin is able to block in vitro cell cycle progression at concentrations similar to serum concentrations observed in vivo, and that this effect is persistent for several days after plitidepsin removal. Whether plitidepsin will prove to be clinically useful in the treatment of undifferentiated thyroid cancers remains to be established. However, our results raise the possibility that plitidepsin might be effective alone or in combination with radiotherapy and/or other drug treatments. 相似文献
43.
44.
Ursula A. Gompels Fernando J. Bravo Sean Briggs Shima Ameri Rhonda D. Cardin David I. Bernstein 《Viruses》2022,14(11)
Herpes simplex virus 1 and 2 infections cause high unmet disease burdens worldwide. Mainly HSV-2 causes persistent sexually transmitted disease, fatal neonatal disease and increased transmission of HIV/AIDS. Thus, there is an urgent requirement to develop effective vaccines. We developed nucleic acid vaccines encoding a novel virus entry complex stabilising cell membrane fusion, ‘virus-like membranes’, VLM. Two dose intramuscular immunisations using DNA expression plasmids in a guinea pig model gave 100% protection against acute disease and significantly reduced virus replication after virus intravaginal challenge. There was also reduced establishment of latency within the dorsal root ganglia and spinal cord, but recurrent disease and recurrent virus shedding remained. To increase cellular immunity and protect against recurrent disease, cDNA encoding an inhibitor of chemokine receptors on T regulatory cells was added and compared to chemokine CCL5 effects. Immunisation including this novel human chemokine gene, newly defined splice variant from an endogenous virus genome, ‘virokine immune therapeutic’, VIT, protected most guinea pigs from recurrent disease and reduced recurrent virus shedding distinct from a gD protein vaccine similar to that previously evaluated in clinical trials. All DNA vaccines induced significant neutralising antibodies and warrant evaluation for new therapeutic treatments. 相似文献
45.
46.
47.
48.
Alejandro Isidoro Pérez Cabeza José Luis Górriz Rafael Bravo Marqués Pedro Antonio Chinchurreta Capote Sergio López Tejero José Antonio González Correa Fidel Ernesto Mesa Prado Almudena Valle Alberca Francisco Ruiz Mateas 《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2021,41(2):216-218
49.
50.